Akebia Therapeutics Inc (NASDAQ: AKBA) is 260.90% higher on its value in year-to-date trading and has touched a low of $0.91 and a high of $4.08 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $3.64 in the last trading session, with the day’s gains setting it 5049996.36%.
Currently trading at $5050000.0, the stock is -2.41% and 18.68% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.02 million and changing -1.92% at the moment leaves the stock 67.91% off its SMA200. AKBA registered 87.89% gain for a year compared to 6-month gain of 84.97%. The firm has a 50-day simple moving average (SMA 50) of $3.0082 and a 200-day simple moving average (SMA200) of $2.1262.
The stock witnessed a 17.82% loss in the last 1 month and extending the period to 3 months gives it a 85.94%, and is -2.72% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.68% over the week and 6.51% over the month.
Akebia Therapeutics Inc (AKBA) has around 181 employees, a market worth around $937.61M and $184.91M in sales. Fwd P/E is 48.24. Profit margin for the company is -24.51%. Distance from 52-week low is 292.31% and -12.41% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.93%).
with sales reaching $47.64M over the same period.The EPS is expected to grow by 80.61% this year, but quarterly earnings will post 24.39% year-over-year. Quarterly sales are estimated to grow 9.14% in year-over-year returns.
Akebia Therapeutics Inc (AKBA) Top Institutional Holders
188.0 institutions hold shares in Akebia Therapeutics Inc (AKBA), with institutional investors hold 40.31% of the company’s shares. The shares outstanding are 261.64M, and float is at 251.57M with Short Float at 7.35%. Institutions hold 38.87% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 11.64 million shares valued at $11.87 million. The investor’s holdings represent 5.5499% of the AKBA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.28 million shares valued at $9.46 million to account for 4.4235 of the shares outstanding. The other top investors are ALERCE INVESTMENT MANAGEMENT, L.P. which holds 5.75 million shares representing 2.7409% and valued at over $5.86 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.1632 of the shares totaling 4.54 million with a market value of $4.63 million.
Akebia Therapeutics Inc (AKBA) Insider Activity
The most recent transaction is an insider sale by Ostrowski Erik, the company’s SVP, CFO, CBO & Treasurer. SEC filings show that Ostrowski Erik sold 41,314 shares of the company’s common stock on Jun 30 ’25 at a price of $3.67 per share for a total of $0.15 million. Following the sale, the insider now owns 0.5 million shares.
Still, SEC filings show that on Jun 09 ’25, Malabre Richard C (SVP, Chief Accounting Officer) disposed off 15,000 shares at an average price of $4.01 for $60150.0. The insider now directly holds 266,914 shares of Akebia Therapeutics Inc (AKBA).
